British life sciences startup Kiin Bio has secured an oversubscribed €1.9 million pre-Seed funding spherical to launch their Digital Scientist Platform for drug discovery, KiinOS – with a later launch of a neighborhood version for researchers scheduled for later this yr.
The funding spherical was led by b2venture with participation from Heartfelt, rule30, and several other strategic angel traders. With the contemporary capital, Kiin Bio will develop its shopper base, improve its AI capabilities, and scale its workforce.
“The way forward for drug discovery isn’t simply higher instruments and information, it’s smarter integration. We see a future the place an AI-driven Platform unifies this fragmented panorama, turning 1000’s of disjointed options right into a cohesive engine for breakthroughs,” stated Filippo Abbondanza, CEO and Co-founder of Kiin Bio. “We’re completely happy to have gained such famend traders who again our mission to construct the pioneering Digital Scientist Platform for drug discovery.”
Based in 2024, Kiin Bio is constructing an AI-native Digital Scientist Platform for drug discovery. Its unified platform integrates digital scientists, an agentic market, and scalable infrastructure to streamline “all the things from literature assessment and bioinformatics by to wet-lab execution“. Backed by traders and energetic pilots by its Frontier Programme, Kiin Bio goals to unify the drug discovery course of with an AI-driven platform designed to speed up analysis and unlock sooner, smarter innovation.
The workforce consists of experience in AI, bioinformatics, cloud infrastructure, and drug discovery:
- Filippo Abbondanza (CEO) holds a PhD in Bioinformatics and was beforehand Product Director at Lifebit, the place he developed and scaled a number of AI-driven platforms to assist pharma determine and analyse the precise information.
- Mark Davies (CDSO – Chief Information and Scientific Officer), brings over 20 years of expertise in growing know-how and information merchandise for all times sciences. He was SVP Informatics & Information at Benevolent AI and beforehand a technical chief at EMBL-EBI, the place he developed main open biomedical assets like ChEMBL and SureChEMBL.
- Bogdan Urse (CTO) is a cloud infrastructure knowledgeable bringing over 10 years of expertise delivering large-scale digital methods throughout a number of cloud suppliers and beforehand labored at Lifebit.
Kiin Bio appears to deal with one of many greatest challenges in drug discovery: the pricey and fragmented R&D course of that may reportedly take as much as 3.7 million hours throughout a whole bunch of scientists to carry a single drug to market.
In accordance with information offered by Kiin Bio, the drug discovery GenAI market is about to generate as much as €96 million within the coming years. Whereas particular person applied sciences exist to assist researchers throughout 1000’s of day by day duties, Kiin Bio believes there is no such thing as a unified framework connecting them, leading to missed productiveness positive factors.
The startup appears to shut this hole by constructing an built-in platform that streamlines your entire course of from discovery to growth.
Already in movement by the Frontier Programme, Kiin Bio has initiated three pilot initiatives, secured three business partnerships and gained an European grant from the ELSA Trade Awards for its AI innovation.
“Kiin Bio is constructing the lacking layer in BioTech: an AI-native agentic infrastructure that redefines how drug discovery is completed, tackling an enormous world, and fragmented market. Their groundbreaking strategy of orchestrating all related instruments and options right into a cohesive Digital Scientist Platform is daring, well timed, and transformative”, stated Andreas Goeldi, Companion at b2venture. “We’re excited to be backing this sturdy workforce. Proper from the beginning now we have been impressed by their distinctive mix of scientific depth, technical execution and enterprise acumen.”
